SMSpilios Manolakopoulos

Spilios Manolakopoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Spilios Manolakopoulos has a total of 446 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increasing HCV Diagnosis and Treatment Uptake Among Community‐Recruited People Who Inject Drugs in Athens, Greece, During the Transition to Unrestricted Access to Direct‐Acting Antivirals

    by Sotirios Roussos, Georgios Papatheodoridis, Theodoros Angelopoulos, Evangelos Cholongitas, Nikolaos Papadopoulos, Spyridon Savvanis, Athina Chounta, Fani Pliarchopoulou, Panagiota Ioannidou, Melanie Deutsch, et al.

    Eliminating hepatitis C requires focusing efforts on people who inject drugs (PWID). The ARISTOTLE HCV‐HIV program aimed to increase HCV and HIV diagnosis and linkage to care among PWID, particularly those currently injecting and not linked to opioid agonist treatment (OAT). This study evaluated HCV diagnosis and linkage to direct‐acting antiviral (DAA) treatment before and after removal of fibrosis‐based treatment restrictions. ARISTOTLE HCV‐HIV (April 2018–February 2020) was conducted in a community setting at a fixed site in central Athens. Two respondent‐driven sampling rounds recruited PWID. Single‐visit procedures included interviews, blood collection, and liver fibrosis assessment. Reflex HCV‐RNA/HCV genotype testing was performed. Participants were linked to collaborating clinicians for DAA treatment. We estimated program reach by exploratory two‐source capture–recapture and constructed HCV care cascades. DAA initiation was assessed from the first visit documenting HCV monoinfection through 180 days after the last such visit. Among 1634 unique participants, 75.0% reported past‐30‐day injecting (exploratory model‐based reach among this population in Athens: 73.2%), 22.9% were currently receiving OAT, and 26.8% were currently homeless. Anti‐HCV prevalence was 76.9% (95% CI: 74.8–78.9), 83.3% (95% CI: 80.8–85.6) of anti‐HCV–positive individuals had viremia. Of 587 monoinfected individuals eligible for treatment, 43.4% initiated DAA. Lifting fibrosis restrictions boosted DAA utilization by 19.2 treatment courses/100 anti‐HCV–positive PWID. DAA access increased substantially after lifting liver fibrosis restrictions. Peer‐driven, community‐based interventions can achieve substantial program reach among underserved PWID and contribute to HCV elimination.

  • Open Access

    Post-SVR Intrahepatic Cholangiocarcinoma: Lessons for Long-Term Surveillance, Biomarker Interpretation, and the Role of Metabolic Dysfunction

    by Eleni Myrto Trifylli, Dimitrios Papanikolaou, Nikolaos Papadopoulos, Stefania Kokkali, Maria Gkotzamanidou, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch

    Sustained virological response (SVR) is considered the gold standard for confirming eradication of hepatitis C virus (HCV) infection and is associated with substantial reductions in liver-related morbidity and mortality. In particular, SVR significantly decreases the risk of primary liver ma-lignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Chronic HCV infection contributes to hepatobiliary carcinogenesis through persistent inflammation and progressive fibrotic remodeling. Although achievement of SVR markedly attenuates ongoing in-flammatory injury, the risk of malignancy is not completely eliminated, particularly in patients with pre-existing architectural liver damage and coexisting metabolic risk factors. Our institu-tional experience includes a case series of 6 out of 17 patients diagnosed with CCA or mixed HCC-CCA between 2023 and 2024, all of whom had a prior HCV infection and achieved SVR, with or without additional cardiometabolic risk factors. Prompted by atypical biomarker profiles and a surveillance strategy primarily focused on HCC, recommended only for patients with prior SVR and advanced fibrosis, we highlight potential diagnostic pitfalls arising from the absence of surveillance in non-cirrhotic SVR patients, despite the persistence of residual cancer risk, particu-larly in those with additional metabolic risk factors. Underdiagnosis of CCA or mixed HCC-CCA may also be contributed to by the limited use of biopsy and reliance on AFP levels and radiologi-cal criteria such as LI-RADS, which are primarily optimized for HCC detection. We therefore support further investigation into CCA risk after HCV cure and advocate for risk-adapted sur-veillance strategies to improve early diagnosis in this patient population.

  • Open Access

    Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence

    by Eleni Myrto Trifylli, Athanasios Angelakis, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Michalis V. Karamouzis, Spilios Manolakopoulos, Melanie Deutsch

    Gastrointestinal (GI) cancers constitute an umbrella term for a wide variety of malignancies that are located in the digestive tract (esophageal, gastric, small and large intestine, anus, liver, gallbladder, and pancreas), with 25% of total cancers and 35% of cancer-related deaths being attributed to them. An alarming trend of rising GI malignancy diagnoses, especially in younger age groups, underscores the need for discoveries in liquid-based biomarkers that facilitate both early detection and optimal disease management. Extracellular vesicles (EVs) not only constitute promising nano-sized biomarkers, but also, via bioengineering, have shown a great therapeutic potential, with artificial intelligence (AI) revolutionizing their research via the selection of the best biomarkers from omics, the recognition of pathophysiological patterns, and facilitating a faster drug-development via AI-driven EV engineering, drug delivery modeling, and target identification. In this review, we will provide a clear insight into the implementation of AI methodologies in EV-based biomarker discovery and therapeutics for pancreatic and hepatobiliary cancer.


  • Open Access

    Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD

    by Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch

    Androgen receptor (AR) signaling has a pivotal role in hepatic lipid homeostasis, as well as in core metabolic functions such as lipogenesis, fatty acid oxidation, and insulin sensitivity. Dysregulation of AR function has been demonstrated in both animal and human studies to disrupt these crucial metabolic pathways, thereby promoting hepatic steatosis. Several causes can lead to AR dysregulation, including genetic mutations or polymorphisms, epigenetic and post-transcriptional modifications, as well as various endocrine disturbances. Prompted by a diagnostically challenging case of a lean 34-year-old male with persistent ALT-predominant transaminasemia, unexplained suboptimal dyslipidemia despite adherence to drug therapy and a healthy lifestyle, and chronically elevated creatine phosphokinase levels irrespective of statin use or exercise intensity, we highlight the overlooked mechanistic link between AR dysfunction and liver–muscle disruption in lean-MASLD patients. Considering the pivotal role of AR in liver–muscle crosstalk, we emphasize the importance of evaluating AR signaling pathways through targeted genetic testing in cases of lean-MASLD among the male population, as well as addressing other extrahepatic manifestations, such as neuromuscular diseases, closely related to AR dysfunction. This clinical strategy may ultimately optimize lean-MASLD management, particularly in view of the emerging utilization of AR-targeted therapeutic modalities, and may also facilitate the management of systemic manifestations associated with altered AR signaling pathways.

  • Open Access

    Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay

    by Eleni Myrto Trifylli, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch

    Hepatobiliary diseases, which include disorders of the liver, gallbladder, and bile ducts, remain a major global health concern. A significant proportion of deaths worldwide are attributed to hepatic diseases, accounting for 4% of the total global mortality in 2023. Among benign hepatobiliary diseases, metabolic dysfunction-associated steatotic liver disease is the most prevalent liver pathology, with a concerning rise in incidence, while it is recognized as the leading cause of liver transplantation in the United States. However, there is a notable rise over time in cases of autoimmune hepatobiliary disorders, including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. Meanwhile, hepatocellular carcinoma still remains the most frequently diagnosed hepatobiliary malignancy, constituting the third leading cause of malignancy-related mortality globally. Meanwhile, cholangiocarcinoma and gallbladder cancer are the second and third most common hepatobiliary malignancies, respectively, both exhibiting highly aggressive malignant behavior. Despite the notable advances in biomarkers and the development of therapeutic tools, early diagnosis and monitoring are considered pivotal for the management of the aforementioned pathologies. The development of new non-invasive biomarkers that can effectively identify, monitor these pathologies, and guide their management is considered a necessity. Extracellular vesicles (EVs) constitute nanoparticles with several embedded cargoes, with a significant role in intercellular communication, which are considered promising biomarkers in several diseases, including viral, metabolic, autoimmune, and malignant diseases. In this review, we will shed light on the role of EVs as novel frontiers in hepatobiliary diseases.


  • Open Access

    Inflammatory Bowel Disease (IBD)-Associated Colorectal Cancer (CRC): Is cGAS-STING Pathway Targeting the Key to Chemoprevention?

    by Stavros P. Papadakos, Chara Georgiadou, Alexandra Argyrou, Elisavet Michailidou, Charalampos Thanos, Stamatina Vogli, Spyros I. Siakavellas, Spillios Manolakopoulos, Stamatios Theocharis

    Inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) remains a significant clinical challenge due to its link with chronic inflammation and the inherent limitations of current prevention and surveillance strategies. The cGAS-STING pathway has emerged as a key player in the immune regulation of inflammation-driven carcinogenesis, demonstrating both protective and pathogenic roles. This review examines the contrasting roles of the cGAS-STING signaling pathway in intestinal inflammation and colitis-associated cancer (CAC), emphasizing its promise as a target for cancer prevention strategies. Evidence suggests that modulating this pathway could preserve epithelial integrity, limit chronic inflammation, and bolster anti-tumor immunity. Despite advancements in therapies like mesalazine and surveillance colonoscopy programs, gaps in efficacy remain, particularly for Crohn’s disease and high-risk populations. Future research should focus on integrating cGAS-STING-targeted approaches with existing modalities to provide personalized and less invasive strategies for CAC prevention. By harnessing this pathway’s therapeutic potential, a paradigm shift in managing IBD-associated CRC may be achieved, addressing the challenges of long-term disease surveillance and prevention.


  • Open Access

    Liver Injury Following Intravenous Methylprednisolone Pulse Therapy in Multiple Sclerosis: The Experience from a Single Academic Liver Center

    by Dimitris Kounatidis, Natalia G. Vallianou, Georgios Kontos, Hariklia Kranidioti, Nikolaos Papadopoulos, Alexandros Panagiotopoulos, Krystalia Dimitriou, Vasileios Papadimitropoulos, Melanie Deutsch, Spilios Manolakopoulos, et al.

    Intravenous methylprednisolone (IVMP) pulses, widely used for managing multiple sclerosis (MS) exacerbations, can lead to acute liver injury, presenting a diagnostic challenge in distinguishing between drug-induced autoimmune-like hepatitis (DI-ALH) and idiopathic autoimmune hepatitis (AIH). This study aimed to delineate the clinical and biochemical features of IVMP-induced liver injury, discern its etiology, and evaluate the efficacy of glucocorticoid (GC) therapy in treatment. A retrospective analysis of 13 relapsing MS patients with IVMP-induced liver injury was conducted. Liver injury was classified as hepatocellular, cholestatic, or mixed, with severity assessment guiding liver biopsy in selected cases. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) and the Simplified Diagnostic Criteria for AIH. All patients were initially monitored for a minimum of six months, with a mean follow-up period of 4.30 years. The median onset of liver injury was 37.46 days post-IVMP, with a mean peak alanine transaminase (ALT) level of 618.46 U/L. antinuclear antibody (ANA) positivity was observed in 61.53% of cases, with elevated serum immunoglobulin G (IgG) at 15.38%. Hepatocellular injury was universal among patients, and causality assessment predominantly supported DI-ALH. GC therapy was administered in six cases, achieving favorable outcomes in all but one, which necessitated rituximab. Biochemical normalization occurred within a mean of 55.41 days, with GC-treated patients recovering faster (48 days). These findings support the hypothesis that IVMP can induce hepatocellular injury, likely DI-ALH, during MS exacerbations. A tapering GC regimen proved effective in promoting recovery, particularly in severe cases. Additionally, this study introduced a diagnostic and therapeutic algorithm for managing IVMP-induced liver injury, offering a practical framework for clinical application.


  • Open Access

    A Systematic Review of Microbiota in Cirrhosis: A Change Towards a More Pathogenic Predisposition

    by Elias Xirouchakis, Alexandros Pelekanos, Spyridon Xirouchakis, Hariklia Kranidioti, Spilios Manolakopoulos

    The microbiome of the human intestine is a regulator of health that modulates immune response and plays an important role in metabolism. The diversity, and abundance of microbiota communities in the gut have been shown to change in cirrhosis and its complications. We aimed to review the current knowledge regarding microbiota alterations in cirrhosis, its potential differences according to etiology, and its role in the development of cirrhosis complications. A systematic search of the online bibliographic database up to July 2024 was performed. Randomized controlled trials and observational and cohort studies that included a total or at least a cohort of cirrhotic adult patients were enlisted for data extraction and analysis. A total of 73 publications were included for data extraction. Alpha diversity was found to decrease in cirrhotic patients in 30/38 (78%) of the studies, while beta diversity in 20/22 (90%) presented significant differences between healthy and cirrhotic groups. Proteobacteria significantly increased in 20/27 (74%) studies, followed by Actinobacteria and Fusobacteria, while 22/25 (88%) studies found either a reduction in cirrhotic patients or increased abundance in healthy controls for Firmicutes and Bacteroidetes. The most abundant genera in hepatic encephalopathy groups were pathobionts such as Enterococcus and Streptococcus, followed by Vellionella and Escherichia. Heterogeneity was found among studies regarding Alpha diversity in hepatocellular carcinoma (HCC) as it was decreased in three studies, indifferent in five, and increased in three studies in comparison to cirrhotic non-HCC patients. The dysbiosis of the gut microbiota is associated with cirrhosis and the development of complications such as hepatic encephalopathy and hepatocellular carcinoma.


  • Open Access

    Systematic Review of the Status of Microbiota in Cirrhosis. A Change Towards a More Pathogenic Predisposition

    by Elias Xirouchakis, Alexandros Pelekanos, Spyridon Xirouchakis, Hariklia Kranidioti, Spilios Manolakopoulos

    Background: The microbiome of the human intestine is a regulator of health by modulating immune response and playing important role in metabolism. Dysbiosis, diversity and abundance of microbiota communities in the gut has shown changes in cirrhosis and its complications. Aim: To review current knowledge regarding microbiota alterations in cirrhosis, its potential differences according to etiology and its role in the development of cirrhosis complications. Methods: A systematic search of online bibliographic database up to July 2024 was performed. Randomized controlled trials, observational and cohort studies that included in total or at least a cohort of cirrhotic adult patients were enlisted for data extraction and analysis. Results: A total of 73 publications were included for data extraction. Alpha diversity was found decreased in cirrhotic patients in 30/38 (78%) of the studies, while beta diversity 20/22 (90%) presented significant difference between healthy and cirrhotic groups. Proteobacteria were significantly increased in 20/27 (74%) studies followed by Actinobacteria and Fusobacteria while 22/25 (88%) studies found either reduction in cirrhotic patients or increased abundance in healthy controls for Firmicutes and Bacteroidetes. The most abundant genera in hepatic encephalopathy groups were pathobionts such as Enterococcus and Streptococcus followed by Vellionella and Escherichia. Heterogeneity was found among studies regarding Alpha-diversity in Hepatocellular Carcinoma (HCC) as it was decreased in 3 studies, indifferent in 5 and increased in 3 in comparison to cirrhotic non-HCC patients. Conclusion: Dysbiosis of the gut microbiota is associated with cirrhosis and development of complications such as hepatic encephalopathy and hepatocellular carcinoma.

  • Open Access

    The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension

    by Elias Xirouchakis, Hariklia Kranidioti, Emilia Hadziyanni, Anastasia Kourikou, Christos Reppas, Maria Vertzoni, Nikolaos Papadopoulos, Melanie Deutsch, George Papatheodoridis, Spilios Manolakopoulos

    Patients with cirrhosis and portal hypertension may have alterations in intestinal barrier resulting in increased susceptibility for infections. We investigated the effect of propranolol in gastrointestinal motility, permeability and bacterial overgrowth in cirrhosis. Patients with cirrhosis and esophageal varices were studied before and after a build-up dose of propranolol according to standard guidelines. Serum TNF-a, IL-6, IL-1b, LPS and bacterial DNA were measured before and during propranolol therapy. Oro-caecal transit time (OCTT) and bacterial overgrowth (BO) have been evaluated with H2 breath testing. Intestinal paracellular (IP), cellular passive non-carrier (ICNC), cellular passive carrier-mediated (ICCM), and gastric permeability (GP) were evaluated by measurement of lactulose, mannitol, D-xylose and sucrose respectively in urine, with high performance liquid chromatography (HPLC). 35 patients with cirrhosis and portal hypertension with median age was 59.6 years (range 42–86) were included in the study. Twenty one had viral hepatitis and 25 were classified as having advanced cirrhosis (Child-Pugh B: 14 or C: 11). Median dose of administrated propranolol was 40 mg/day. After 7 days propranolol treatment BO was resolved in 15 out of 16 patients (93.7%, p = 0.0001) and OCTT was reduced significantly from 180 min to 139 min (SD 58.5, difference − 4 1 min, p = 0.0001). Serum IL-6 levels were reduced in 21/35 (60%) patients from 41.1 to 19 pg/ml (p = 0.01), TNF-a in 10/35 (28.5%) patients from 10.7 to 5.6 pg/ml (p = 0.007) and LPS in 20/35 (57%) from 7.1 to 5.2 mg/L (p = 0.1). No bacterial DNA was detected in serum of all patients either baseline or under propranolol treatment. IP was significantly reduced (0.2 to 0.16, p = 0.04) whereas ICNC (p = 0.9), ICCM (p = 0.4) and GP (p = 0.7) were not affected significantly. Intestinal Permeability (PI) index (Lactulose to Mannitol ratio) was significantly reduced (0.027 to 0.02, p = 0.03). In patients with cirrhosis and portal hypertension, propranolol use is associated with reduction in BO, increase in intestinal motility and amelioration in intestinal permeability. Moreover IL-6 and LPS levels are being decreased in the majority of patients under propranolol.